KEY FINDINGS: The findings suggest that infliximab or corticosteroids may be more effective than anakinra as adjunctive treatment for IVIG-resistant MIS-C. However, the relatively small sample and limited statistical power warrant caution when interpreting the results. Further research is needed to guide treatment selection.
BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a serious inflammatory condition associated with SARS-CoV-2 infection. Although intravenous immunoglobulin (IVIG) is commonly used, some children require additional anti-inflammatory treatment. This study compared infliximab, methylprednisolone and anakinra as adjunctive therapies for IVIG-resistant MIS-C.
DETAILS: The study enrolled 73 children with IVIG-resistant MIS-C at two hospitals; 71 received their first randomized treatment and completed the study. The primary outcome was the need for a second randomization following initial treatment. The investigators compared infliximab, methylprednisolone and anakinra, assessing treatment response and adverse events.
After adjustment for age and sex, the odds of requiring a second randomization were significantly higher with anakinra than with infliximab (OR 3.42; 95% CI 1.03–12.29; P = .049). The odds were similar between the methylprednisolone and infliximab groups. Twenty-eight adverse events were recorded, none serious. Of the 17 events considered possibly, probably or definitely treatment-related, 16 (94.1%) were attributed to steroids and one (5.9%) to anakinra.
Copyright © Skyscape. All rights reserved.
Source: Jain, S., He, F., Cheng, Y., et al. Multisystem Inflammatory Syndrome Therapies in Children: A Comparative Effectiveness Trial. The Journal of Pediatrics. 2026; 299:115293. Published: December, 2026. DOI: 10.1016/j.jpeds.2026.115293.
KEY FINDINGS: Approximately 30% of infants with FoCHI showed early spontaneous glycemic improvement. Although surgery remains the standard curative treatment, carefully selected infants with favourable early glucose control may be considered for conservative management, particularly when pancreatic head surgery carries substantial risk. The predictive score is exploratory and requires further validation. Close glucose monitoring and specialist assessment remain essential before deferring surgery.
BACKGROUND: Congenital hyperinsulinism (CHI) is the most common genetic cause of hypoglycemia in infants. In focal congenital hyperinsulinism (FoCHI), excessive insulin secretion originates from a localized pancreatic lesion that can often be surgically removed. However, surgery, particularly involving the pancreatic head, carries a risk of postoperative complications.
DETAILS: Researchers retrospectively reviewed 39 patients treated at a single referral centre. Patients were classified according to whether continuous gastric tube feeding was required to maintain glucose control: 12 patients (30.8%) were in the no-tube-feeding (NTF) group and 27 (69.2%) in the tube-feeding (TF) group. The NTF group had later diagnosis (P = .022) and less severe initial hypoglycemia (P = .003). An exploratory predictive score for early disease evolution demonstrated 97% specificity.
Four of the 12 patients in the NTF group experienced spontaneous resolution of hypoglycemia before 6 years of age and did not require surgery. Surgery was curative in 96.3% of the TF group and 100% of the NTF group. Long-term complications occurred in 8.6% and 0%, respectively, and consisted exclusively of exocrine pancreatic insufficiency. This complication occurred only after pancreatic head surgery, affecting 15.8% of patients undergoing that procedure.
Copyright © Skyscape. All rights reserved.
Source: Arnoux, J. B., Mayer, C., Jhaouat, I., et al. Focal congenital hyperinsulinism: spontaneous glycemic improvement before surgery. The Journal of Clinical Endocrinology & Metabolism. 2026; 111(11): 3032-3041. Published: November 22, 2026. DOI: 10.1210/clinem/dgag227.
KEY FINDINGS: The outbreak is caused by Bundibugyo virus, a distinct Ebola virus species for which no licensed vaccine or specific treatment is currently available. This limits the availability of virus-specific medical countermeasures and reinforces the importance of early diagnosis, supportive clinical care, and rigorous infection prevention and control.
Healthcare facilities should maintain heightened awareness of compatible illness in patients with relevant travel or exposure histories. Prompt identification, appropriate isolation, laboratory testing, contact tracing, and coordinated public health response remain critical to reducing transmission. ECDC continues to monitor the outbreak and provide epidemiological updates and risk assessments.
BACKGROUND: An outbreak of Ebola disease caused by Bundibugyo virus (BDBV) has been ongoing in the Democratic Republic of the Congo (DRC) since May 2026. The outbreak has expanded beyond the DRC, with imported cases reported in Kenya and Nigeria during October. The emergence of cases across multiple countries underscores the importance of early case recognition, cross-border surveillance, infection prevention and control (IPC), and coordinated public health preparedness.
DETAILS: According to the European Centre for Disease Prevention and Control (ECDC), as of 29 October 2026, the DRC had reported 10,274 confirmed cases and 4,992 related deaths, based on data through 28 October. Community transmission continues across eight provinces. Kenya reported nine confirmed cases, including two deaths, as of 26 October. All cases were epidemiologically linked to the initial imported case, with no evidence of wider community transmission reported in the available assessment. The second death was reported on 23 October in a patient who was the third confirmed case in the Kenyan cluster.
Nigeria reported an Ebola case on 20 October in an individual with a travel history to Uganda. The patient was subsequently medically evacuated to Switzerland. As of 29 October, 62 contacts had been identified and were under follow-up. Epidemiological investigations and contact tracing remain ongoing.
The outbreak continues to pose a substantial public health challenge, particularly in the DRC, where sustained community transmission and high mortality have been reported. The expansion into Kenya and Nigeria highlights the potential for international spread through population movement and travel.
In Kenya, the identification of nine cases, including two deaths, within a single epidemiologically linked cluster suggests that contact tracing and isolation have been central to containing transmission. However, the continued occurrence of cases requires sustained monitoring. ECDC emphasizes that the outbreak may be larger than currently reported because of gaps in epidemiological information and incomplete contact follow-up.
Copyright © Skyscape. All rights reserved.
Source: European Centre for Disease Prevention and Control (ECDC). Ebola disease: Multi-country outbreak 2026. ECDC. 2026; Published: October 30, 2026.
A Systematic Review and Meta-Analysis of Randomized Controlled Trials
[Posted 29/Oct/2026]
AUDIENCE: Dermatology, Pediatrics, Family Medicine
KEY FINDINGS: Oral JAK inhibitors improve hair regrowth in adults with moderate-to-severe alopecia areata, with increasing treatment effects observed at later assessment points through 36 weeks. Although overall adverse events were more frequent than with placebo, the analysis did not demonstrate statistically significant differences in serious adverse events or adverse event-related treatment discontinuation. Interpretation requires caution because only one included trial enrolled adolescents, and half of the trials had some concerns about risk of bias, primarily related to missing outcome data. Head-to-head trials and longer-term safety surveillance are needed to clarify comparative effectiveness and the durability of treatment responses.
BACKGROUND: Alopecia areata is an autoimmune disorder that causes nonscarring hair loss and may progress to complete scalp or body hair loss. Oral Janus kinase (JAK) inhibitors target inflammatory signaling pathways involved in hair follicle damage and have expanded treatment options for moderate-to-severe disease. This systematic review and meta-analysis evaluated their efficacy and safety in adults and adolescents compared with placebo.
DETAILS: The review included 12 randomized controlled trials involving 4,141 participants, with a mean age of 35.8 years and a mean baseline Severity of Alopecia Tool (SALT) score of 86.0. Eligible participants were aged 12 years or older. All included trials enrolled adults, except one trial in which adolescents accounted for 15% of participants. The investigators assessed hair regrowth using SALT thresholds of 10 or less and 20 or less, along with improvements of at least 50%, 75%, and 90% from baseline. Treatment-related adverse events were also evaluated. The literature search covered MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials through November 28, 2025.
Oral JAK inhibitors were significantly more effective than placebo across all primary efficacy outcomes. At week 24, the odds of achieving a SALT score of ≤10 were 5.69 times higher with JAK inhibitor treatment (OR, 5.69; 95% CI, 3.58-9.03). By week 36, the odds ratio increased to 9.40 (95% CI, 4.58-19.29). For achieving a SALT score of ≤20 at week 24, the OR was 7.99 (95% CI, 5.13-12.44). Treatment also significantly increased the likelihood of achieving SALT50, SALT75, and SALT90 responses across assessment time points from weeks 12-36. Safety analyses showed a higher risk of total adverse events with JAK inhibitors than with placebo (OR, 1.60; 95% CI, 1.33-1.94). However, differences in serious adverse events (OR, 1.04; 95% CI, 0.69-1.57) and treatment discontinuation due to adverse events (OR, 1.22; 95% CI, 0.84-1.76) were not statistically significant.
Copyright © Skyscape. All rights reserved.
Source: Morriss, S., Foo, C. H., Lin, E., et al. Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. American Journal of Clinical Dermatology. 2026; 27(5): 925-943. Published: October, 2026. DOI: 10.1007/s40257-026-01060-z.
KEY FINDINGS: Working memory updating develops substantially during childhood, with the greatest improvements observed between ages 3 and 8. The subsequent slowing of gains suggests that cognitive development in this domain is nonlinear. Differences across task types are also important when interpreting cognitive assessments, comparing children of different ages, or evaluating developmental interventions. The findings support the use of age-appropriate assessment tools and caution against assuming that all working memory updating tasks measure developmental change in the same way.
BACKGROUND: Working memory updating is an executive cognitive function that enables individuals to replace outdated information with relevant new information. It supports learning and academic achievement, but its development across childhood and adolescence-and the extent to which developmental patterns differ by assessment task-has not been fully characterized.
DETAILS: Ye Song and Chen Cheng conducted a meta-analysis of 99 studies involving 35,858 participants aged 3-17 years. The analysis examined age-related changes in working memory updating across different assessment paradigms and compared linear and quadratic models of developmental progression. Task-specific analyses evaluated whether developmental patterns differed according to the type of updating task used.
Working memory updating performance improved significantly with age, with the largest gains occurring during early to middle childhood (ages 3-8; d = 2.29). Both linear and quadratic models described the developmental trajectory, but the quadratic model provided a better fit, indicating that improvements were steeper in early childhood and gradually slowed during adolescence. Developmental patterns also varied by task. Backward recall tasks demonstrated the strongest age-related improvement (β = .21), whereas n-back and selective updating tasks showed relatively flat developmental trajectories. These findings indicate that estimates of working memory development may depend substantially on the assessment paradigm used.
Copyright © Skyscape. All rights reserved.
Source: Song, Y. and Cheng, C. The developmental trajectories of working memory updating from early childhood to adolescence: A meta-analysis. British Journal of Psychology. 2026; 117(4): 1367-1395. Published: November, 2026. DOI: 10.1111/bjop.70069.
KEY FINDINGS: Triplet pregnancies managed without embryo reduction were associated with substantially higher risks of early PE than singleton and twin pregnancies. Reduction from triplets to twins was associated with a lower risk of PE before 34 weeks than in non-reduced triplets, although risk remained elevated relative to twin pregnancies. Following reduction to a singleton, PE risk was comparable to that observed in singleton pregnancies, but the reduced sample size of 96 pregnancies warrants caution when interpreting this finding. The authors estimated that PE-associated delivery occurred, on average, 14.5 weeks earlier in non-reduced triplets, 12.7 weeks earlier in triplets reduced to twins, and 6.5 weeks earlier in triplets reduced to singletons than in comparable singleton pregnancies. These findings may inform risk assessment and counseling in pregnancies initially diagnosed as triplets.
BACKGROUND: Pre-eclampsia (PE) is an important cause of maternal and perinatal morbidity and mortality. Although multiple pregnancies are associated with greater PE risk than singleton pregnancies, evidence regarding the incidence and timing of PE in triplet pregnancies, particularly following embryo reduction, has been limited. This study examined PE risk in triplet pregnancies managed expectantly or reduced to twins or singletons, using twin and singleton pregnancies as comparators.
DETAILS: This retrospective multicenter study included 1,020 triplet pregnancies with three live, phenotypically normal fetuses at the 11-13-week ultrasound examination and delivery at a gestational age of ≥24 weeks. Of these, 456 pregnancies were managed expectantly, 468 underwent embryo reduction to twins, and 96 were reduced to singletons. Outcomes were compared with previously collected data from 1,169 twin pregnancies and 61,174 singleton pregnancies. The primary assessments included PE incidence associated with delivery before 37, 34, and 32 weeks of gestation and the relative risk compared with singleton and twin pregnancies.
The incidence of PE associated with delivery before 37 weeks was 9.9% in non-reduced triplet pregnancies, 9.8% following reduction to twins, 2.1% following reduction to singletons, 7.0% in twin pregnancies, and 0.8% in singleton pregnancies. Before 34 weeks, the respective incidences were 7.2%, 4.1%, 0%, 0.9%, and 0.4%. Before 32 weeks, PE incidence was 3.1% in non-reduced triplets, 1.5% in triplets reduced to twins, 0% in triplets reduced to singletons, 0.6% in twins, and 0.2% in singletons. Compared with singleton pregnancies, non-reduced triplet pregnancies had relative risks of 12.3 (95% CI, 9.1-16.3) for PE associated with delivery before 37 weeks and 20.6 (95% CI, 14.4-29.2) before 34 weeks. For triplet pregnancies reduced to twins, the corresponding relative risks were 12.2 (95% CI, 9.1-16.2) and 11.6 (95% CI, 7.3-18.2). Compared with twin pregnancies, non-reduced triplets had relative risks of 1.4 (95% CI, 1.0-2.0) before 37 weeks and 7.7 (95% CI, 4.0-14.9) before 34 weeks. Triplet pregnancies reduced to twins had corresponding relative risks of 1.4 (95% CI, 1.0-2.0) and 4.3 (95% CI, 2.1-8.9).
Copyright © Skyscape. All rights reserved.
Source: Yerlikaya-Schatten, G., Wright, A., Kristensen, S., et al. Incidence of pre-eclampsia in triplet pregnancies with and without embryo reduction. Ultrasound in Obstetrics & Gynecology. 2026; 68(4): 504-509. Published: September, 2026. DOI: 10.1002/uog.70341.
Specialty: